Pfizer has struck a deal worth up to $350 million with Biocon Ltd., the company that claims to be India’s biggest biotech drugmaker. The two will collaborate on diabetes drugs, combining Pfizer’s marketing power and Biocon’s low-cost manufacturing ability. Biosimilars are a hot item throughout the world. Although India currently has a lead over China in cGMP biologics manufacturing, China is racing to catch up. More details....

Stock Symbol: (NYSE: PFE)